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Objectives: to study whether Chlamydia pneumoniae (Cpn) infection affects atherosclerotic plaque morphology in
atherogenic (LDLr/ApoEÿ/ÿ) mice.
Methods: in mice sacrificed 20 or 40 weeks after Cpn infection aortic arch sections were analysed for lesion and fibrous cap
area and the presence of matrix metalloproteinases (MMP)-2 and -9.
Results: all infected mice seroconverted, demonstrated Cpn DNA in their aortas on PCR and developed atherosclerotic
plaques. Infection was not associated with changes in lesion area or type, but was associated with reduced the fibrous cap
area and increased MMP-2 and -9 immunoreactivity.
Conclusion: these findings suggest that Cpn infection may predispose to plaque instability.
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Introduction
Several viruses and bacteria, but especially Chlamydia
pneumoniae (Cpn), have been implicated in the devel-
opment and progression of atherosclerosis and
cardiovascular disease,1±6 although the mechanisms
involved remain speculative. In vitro, Cpn induces
foam cell formation,7 smooth muscle cell prolifera-
tion,8 the endothelial expression of adhesion mole-
cules and chemokines and the production of matrix
metalloproteinase.9,10 Studies in hypercholesterolemic
mice11 and rabbits12 indicate that Cpn can increase
lesion size. However, atherosclerotic lesion size may
not be the most important risk factor for cardiovas-
cular complications. Instead, lesion type, as defined
by the American Heart Association13 may be a more
important denominator for the severity of the dis-
ease process and the risk for future complications.
Interestingly, we recently demonstrated an acceler-
ation in complex lesion formation in ApoE3-Leiden
mice following Cpn infections without alterations in
total lesion size.14
Acute coronary syndromes (unstable angina, acute
myocardial infarction, and ischemic sudden death)
result from coronary thrombosis superimposed on
an atherosclerotic plaque. Thrombosis is generally a
consequence of disruption of the atherosclerotic pla-
que in the form of a fissure/rupture in the fibrous
cap overlying a lipid-rich pool. Inflammation with
accumulation of activated mononuclear cells may
play a potential role in plaque disruption through
the elaboration of proteases, such as matrix degrad-
ing metalloproteinases (MMP). Since Cpn has been
shown to stimulate the production of MMPs by
macrophages9,10 we hypothesized that Cpn infection
may activate MMPs in the atherosclerotic plaque,
thereby degrading the overlying fibrous cap and
create a more vulnerable atherosclerotic plaque in
the long run. Rupture of such a vulnerable plaque
may result in acute cardiovascular complications,
which may explain earlier findings associating posi-
tive Cpn serology with myocardial infarction, per-
ipheral arterial disease and stroke.4,15,16 To explore
this hypothesis we infected ApoE/LDLrÿ/ÿ mice
frequently with Cpn and evaluated atherosclerotic
lesion size and type, the presence of MMP-2 and
-9 and fibrous cap thickness in the aortic arch of
these mice.
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Methods
Mice
Thirty-two, male specific pathogen free LDLr/
ApoEÿ/ÿ mice on a C57Bl/6J background (gift from
Dr JW van der Meer, Department of Internal Medi-
cine, Nijmegen University, The Netherlands) were
housed under standard conditions at the Central
Animal Facility at the Maastricht University. During
the study, the mice were fed a normal chow diet
(Hopefarms BV, Woerden, The Netherlands) and tap
water ad libitum. This study was approved by the
institutional committee for the welfare of laboratory
animals of the Maastricht University.
Chlamydia pneumoniae (Cpn)
Cpn strain TWAR 2043 (ATCC VR-1355) was cultured
in Hep-2 cells as previously published.17 Bacterial
titres were determined by titration in Hep-2 cells and
stained with FITC-conjugated monoclonal antibody
RR 402 (Dako, Denmark). Titers were expressed as
number of inclusion forming units per millilitre
(IFU/ml).
Experimental design
As it has been demonstrated that multiple infections
result in enhanced atherosclerosis14,18 we decided to
infect our mice 2 or 6 times with Cpn. At the age of 16
weeks, all mice were infected intraperitoneally with
Cpn or mock infected with sucrose-phosphate-glucose
solution (SPG, solution in which Cpn is stored). Mice
in group A received a second inoculation (5  106 IFU
Cpn or mock, n 8/8) at the age of 18 weeks and were
sacrificed at the age of 20 weeks. Mice in group B
(n 7/7) received six successive monthly infections
(first infection with 5.107 IFU Cpn and following infec-
tions with 5  106 IFU Cpn) or mock injections and were
sacrificed 1 month after the last infection (at 40 weeks).
Tissue handling
At sacrifice the mice were anaesthetised with a
weight-adjusted dose of pentobarbital (Nembutal1,
Sanofi BV, Maassluis, The Netherlands) and blood
was collected from the left ventricular apex of the
heart for analysis of anti-Cpn antibodies. The arterial
tree was perfused with phosphate-buffered saline
(PBS) through a catheter placed in the left ventricular
apex. The aortic arch with main branchpoints was
removed, fixed overnight in 3.7% PBS buffered for-
maldehyde and embedded in paraffin. Serial longitu-
dinal 4 mm sections of the aortic arch were cut, stained
and analysed. Thoracic and abdominal aorta, lung,
spleen, heart and brain were dissected and stored at
ÿ70 C for Cpn DNA analysis.
Atherosclerotic lesion analysis
Only aortic arches with an intact morphology (bra-
chiocephalic trunk, left and right common carotid
artery and left subclavian artery) were used. Of the
entire arch, longitudinal, coronal, consecutive sections
were cut and used for analysis of atherosclerotic lesion
type and lesion area. The number of sections obtained
from each arch was calculated and then the middle
section was haematoxilin-eosin (HE) stained for
analysis of atherosclerotic lesion types according to
the guidelines of the American Heart Associ-
ation.13,14,19 The total number of all lesions was calcu-
lated and the contribution of each lesion type to the
total number of lesions was expressed as a percentage
of the total lesion number.
Total lesion area was determined in the same HE-
stained section used for lesion type analysis. For area
analysis a microscope coupled to a computer-assisted
morphometry system (Analysis Soft Imaging System,
GmbH, MuÈ nster, Germany) was used.
Detection and evaluation of cap area in
atherosclerotic lesions
To analyse the presence of smooth muscle cells (SMC)
in the lesion, a mouse monoclonal antibody toa-smooth
muscle cell actin (Sigma, St Louis, MO, U.S.A.) was
used. The primary antibody was conjugated with a
biotin labelled goat-anti-mouse IgG. Sections were
then incubated with an alkaline phosphatase coupled
ABC reagent (Dako, Glostrup, Denmark) and alkaline
phosphatase activity was visualised using Fast-red
(Sigma, St Louis, MO, U.S.A.). Normal mouse ascitic
fluid (Sigma-Aldrich Chemie BV, Zwijndrecht, The
Netherlands) was used as negative control. Since the
media of the vessel wall mainly consists of SMC, this
part of the slide was used as positive control. For
quantification of fibrous cap area, SMC positive area
in the atherosclerotic lesion was analysed using a
microscope coupled to a computer assisted morpho-
metry system (Analysis Soft Imaging System, GmbH,
MuÈ nster, Germany). The results were expressed as
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area SMC/total lesion area and are designated as
cap area.
Detection and evaluation of matrix
metalloproteinases-2 and -9 in the plaque
Presence of matrix metalloproteinases (MMP)-2 and -9
in the plaque was detected by staining with mouse-
anti-MMP-2 and -9 monoclonal antibody (Oncogene
Research Products, Cambridge, U.K.). The primary
antibody was conjugated with a biotin labelled goat-
anti-mouse IgG. Sections were then incubated with an
alkaline phosphatase coupled ABC reagent (Dako,
Glostrup, Denmark) and alkaline phosphatase activity
was visualised using Fast-red (Sigma, St Louis, MO,
U.S.A.). Normal mouse ascitic fluid (Sigma-Aldrich
Chemie BV, Zwijndrecht, The Netherlands) was used
as negative control. For positive controls mouse heart
sections were used.
MMP-2 and -9 staining was analysed by semi-
quantitative measurements using 0no staining,
1positive staining and 2 extensive positive
staining. Mean score of all aortic arch sections was
calculated and results of Cpn- and mock-infected
mice were compared.
Detection of anti-Cpn antibodies and Cpn DNA
Anti-Cpn antibodies were measured with the indirect
micro-immunofluorescence (MIF) technique using
mouse plasma sample dilutions 1:10 and 1:100 on
antigen-coated slides (Labsystems, Helsinki, Finland).
Goat-anti-mouse IgG conjugated to FITC (Sigma) was
used as the secondary antibody. The slides were
analysed by 2 independent observers. To detect the
presence of Cpn DNA in the organs, a sensitive poly-
merase chain reaction (PCR) was used (detection
ability of 1 copy of DNA). The following sequences
were used as primers: sense CPC, 50-TTA TTA ATT
GAT GGT ACA ATA-30; antisense CPD, 50-ATC TAC
GGC AGT AGT ATA GTT-30.20
PCR was performed in a total volume of 50:1, con-
taining 1 mg DNA. DNA was extracted from vascular
tissue, lung, spleen, heart and brain with the Wizard
Genomic DNA purification kit (Promega, Germany).
Amplification was done by thermal cycling starting at
37 C for 10 min and 95 C for 15 min. Then 20 cycles
of `` Touchdown PCR'' were performed from 60 to 50 C,
followed by 40 cycles of 1 min at 94, 50, and 72 C.
The PCR products were resolved in a 2% agarose
gel, stained with ethidium bromide, and photo-
graphed.
Statistical analysis
The difference in lesion type, size, cap area and
MMP-2 and -9 between the Cpn-infected and
mock-infected mice was analysed with the
Mann±Whitney U-test. A p-value of 50.05 was con-
sidered statistically significant. Data are expressed as
mean+ sd. Analysis of sections was done by an
impartial observer who was blinded with respect to
the presence or absence of Cpn as well as to the
time point of sacrifice.
Results
To study the role of Cpn infection on atherosclerotic
plaque phenotype, 32 LDLr/ApoEÿ/ÿ mice were
infected, sacrificed and analysed. Two mice in group
B (one Cpn-infected and one mock-infected mouse)
died before reaching time point of sacrifice and were
excluded from the study. The cause of death remained
unknown.
Cpn infection has no effect on atherosclerotic
lesion type or lesion area
The type of atherosclerotic lesion in the aortic arch
was analysed according to the guidelines of the
American Heart Association.13,14 All mice in group A
and B developed atherosclerotic lesions ranging from
type 2 to type 5b lesions. No initial lesion type 1 and
no complicated lesion type 6 were observed (Table 1).
Since the complexity of the atherosclerotic lesion types
increases in time, more advanced lesion types, espe-
cially type 5b, were found in group B (sacrifice at 40
weeks of age) when compared to group A (sacrifice at
20 weeks of age) where type 4 and 5a lesions were
predominant (Table 1). No statistical significant differ-
ence could be detected in the distribution of the lesion
types in Cpn-infected and mock-infected mice of
group A and B.
The HE-stained sections used for classification of
atherosclerotic lesion types were also used for deter-
mination of lesion area. Data on the total lesion area
are presented in Table 1. No statistical significant dif-
ferences in lesion area could be detected between
Cpn-infected and mock-infected mice either in both
group A or B. These data reveal that Cpn infection
does not affect atherosclerotic lesion type or area in
LDLR/ApoEÿ/ÿ mice when these mice are infected at
a stage when advanced atherosclerotic lesions are
already present.
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Cpn infection reduces atherosclerotic
fibrous cap area
The fibrous cap area (expressed as SMC positive area/
total lesion area) of the atherosclerotic lesions was
determined in aortic arch sections of Cpn-infected
and mock-infected mice of group A and B.
Positive a-smooth muscle cell actin staining was
mainly concentrated in the fibrous cap of the athero-
sclerotic lesion (Figs 1A and B) with very few diffuse
staining in the rest of the plaque.
The cap area was measured in all atherosclerotic
lesions. When the fibrous cap areas in the Cpn-
infected and mock-infected mice of group A and B
were compared, an effect of Cpn infection was found
on the fibrous cap area in the lesion. In particular, as
shown in Figure 2, infection resulted in a significant
decrease in cap area from 0.26 0.17 to 0.09 0.15
(p5 0.001, Fig. 1A) in group A and from 0.10+ 0.08
SMC/lesion area to 0.05+ 0.14 (p5 0.01, Fig. 1B) in
group B. These results demonstrate that Cpn infec-
tion reduces the atherosclerotic fibrous cap area
thereby inducing a vulnerable, more unstable plaque
phenotype.
Furthermore, when fibrous cap area of atheroscler-
otic lesions in mock-infected mice was determined a
significant decrease was observed from 0.26 0.17 in
group A to 0.10 0.08 in group B (p5 0.001), suggest-
ing that older control mice develop unstable plaques
as well.
Cpn infection enhances MMP-2 and -9
in the plaque
MMP-2 and -9 antigens in the atherosclerotic lesions
were determined semi-quantitatively using immuno-
histochemical stained sections of the aortic arch.
MMP-2 and -9 positive staining was mainly concen-
trated in the endothelial layer, necrotic core and shoul-
der region of the atherosclerotic lesion (Fig. 1C). When
the presence of MMP-2 and -9 in the lesions of
Cpn- and mock-infected mice of group A and B was
compared, an increase in MMP-2 and MMP-9
immunoreactivity was observed in Cpn-infected
mice. In group A, MMP-9 positive staining increased
from 0.25 0.46 in mock-infected mice to 0.75 0.46 in
Cpn-infected mice (p5 0.05, Table 2), while in group B
MMP-9 positive staining increased from 0.57+ 0.53 in
control mice to 0.86+ 0.38 in Cpn-infected mice (NS).
Furthermore, MMP-2 positive staining was detected
more frequently (1.5+ 0.55) in Cpn-infected mice
from group A than in control mice (0.83+ 0.41,
p5 0.05). A similar result was obtained in mice of
group B. In this group MMP-2 positive staining was
more frequently observed in Cpn-infected mice
(1.43+ 0.53) than in mock-infected mice (1.00+ 0.00,
p5 0.05).
Cpn infection
All Cpn-infected mice seroconverted after inocula-
tions with Cpn, indicating that mice had indeed been
successfully infected. In all these mice anti-Cpn
antibodies were found at plasma dilutions of 1:10
and 1:100. No anti-Cpn antibodies were detected in
plasma of mock-infected mice.
Successful inoculation was confirmed by our PCR
results. Cpn DNA was detected in all aorta of group
A showing that intra-peritoneal infection resulted in
dissemination to the vessel wall in all cases. Cpn
DNA could also be detected in various organs
(aorta, spleen, lung, heart and brain tissue). In
group B, the percentage of Cpn positive aortic sam-
ples was slightly lower compared to group A (100 vs
43%) indicating that the murine immune system is
able to eradicate Cpn in the long run. In a similar
way lower percentages of Cpn DNA positive organs
were observed in group B (data not shown). No
positive results were obtained in the mock infected
group.
Table 1. Atherosclerotic lesion types and lesion area in Cpn- and mock-infected mice.
Group Inoculation
(number of mice)
Lesion type  Lesion area
(mm2)
1 2 3 4 5a 5b
Group A
Cpn (8) ± ± 17 1 36 2 39 1 8 1 0.24 0.20
Control (8) ± 2 0 13 1 28 1 30 1 26 1 0.22 0.20
Group B
Cpn (7) ± 6 1 3 0 19 1 17 1 56 2 0.66 0.46
Control (7) ± ± 6 1 14 1 28 1 53 2 0.75 0.54
Presence of atherosclerotic lesion type is expressed as percentage sd ± Lesion type is not present. Total lesion area is
expressed as the mean sd.
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Fig. 1. Immunohistochemical staining showing a-smooth muscle cell actin and MMP-9 staining. Positive a-smooth muscle cell actin staining
in Cpn- (A) and mock-infected (B) mice, magnification 25 MMP-9 staining in atherosclerotic lesion of Cpn-infected (C) mouse, magni-
fication 25 and mock-infected mouse (D), magnification 100.
Fig. 2. (A) Cap area in the atherosclerotic lesion of Cpn- and mock-infected mice in group A. The values are presented as SMC area divided
by plaque area. p5 0.001. (B) Cap area in the atherosclerotic lesion of Cpn- and mock-infected mice in group B. The values are presented as
SMC area divided by plaque area. *p5 0.001.
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Discussion
Since the first report on the association between Cpn
infection and coronary heart disease by Saikku et al.4
various clinical and experimental studies have con-
firmed1,2 the possible contribution of Cpn infection
in atherosclerotic plaque development and clinical
symptoms such as myocardial infarction or stroke.
However, the mechanism by which Cpn infection con-
tributes to progression of atherosclerosis has not been
clarified yet. Here we present evidence that Cpn infec-
tions may contribute to the reported cardiovascular
complications not by increasing the atherosclerotic
plaque size but by inducing an unstable, rupture
prone plaque by reducing the fibrous cap on top of
the atherosclerotic lesion.
In the first part of this study we focused on Cpn
induced alterations in total atherosclerotic lesion size.
Sixteen week old LDLr/ApoEÿ/ÿ mice were infected
twice or six times on a monthly base and total lesion
area was analysed in the aortic arch of these mice.
Nonetheless, no differences were found in total lesion
area. This finding is in accordance with previous
results from our14 and other groups.21,22 However,
others reported an increase in total lesion area follow-
ing repeated Cpn infection in ApoEÿ/ÿ or LDLrÿ/ÿ
mice.11,18 The reason for this discrepancy may reside
in different Cpn strains used by different groups, dif-
ferent age at which the mice receive the first inocula-
tion, the frequency of infections or the route of
inoculation.
Since it is recognised that plaque morphology is a
more important determinant of clinical manifestations
of atherosclerosis than the degree of stenosis,
expressed as lesion area,23 we also studied to what
extent different lesion types13 contributed to the total
atherosclerotic burden in these mice following multiple
Cpn infections. In a previous study we demonstrated
that Cpn infection significantly accelerated the
formation of advanced atherosclerotic plaques in
ApoE3-Leiden mice without alterations in total lesion
size.14 However, in contrast to our previous findings
in ApoE3-Leiden mice no acceleration of the athero-
sclerotic plaque formation was observed in 20 or 40
week old LDLr/ApoEÿ/ÿ mice following multiple
Cpn infections. The reason for this inconsistency may
be related to the fact that in these LDLr/ApoEÿ/ÿ
mice advanced lesions (type 4±5) are already the pre-
dominant phenotype at the age of 16 weeks while in 8
week old ApoE3-Leiden mice initial plaques (type 2±3)
are the principal phenotype. Initial lesions mainly
consist of macrophages infiltrating the vascular wall
while advanced lesions contain a large necrotic core
with extracellular lipids and cholesterol-ester crystals,
extracellular matrix components (collagen) and smooth
muscle cells. As macrophages are used as vehicle by
Cpn for dissemination from the site of infection to
different organs throughout the whole body (includ-
ing the vessel wall),24 it may be anticipated that it is
more easy for Cpn to enter an initial atherosclerotic
plaque and exert its proatherogenic effect than to enter
an advanced lesion. This may explain why Cpn infec-
tions during the initial stages of atherosclerosis may
accelerate the process while infections may have no
effect on lesion progression when the plaques are
already in a more advanced stage.
Cardiovascular complications mainly occur as a
result of erosion or uneven thinning and rupture of
the fibrous cap on top of an atherosclerotic lesion.
Rupture of the fibrous cap exposes thrombogenic
material, thereby initiating platelet aggregation and
coagulation in the infiltrating and overlying blood.
The expansion of thrombogenic plaque contents into
the lumen then results in sudden occlusion or embo-
lisation resulting in, e.g., myocardial infarction or
stroke.25,26 Degradation of the fibrous cap may result
from activation of metalloproteinases such as collage-
nases, elastases and stromelysins.27 Since Cpn has
been shown to stimulate the MMP-2 and -9 produc-
tion by macrophages in a concentration dependent
way9,10 we examined whether Cpn infection inter-
fered with the fibrous cap formation in LDLr/
ApoEÿ/ÿmice. As the fibrous cap is mainly composed
of SMCs, the SMC content of atherosclerotic plaques
in the aortic arch of these mice was determined. In
group A as well as in group B we found a significant
reduction in the SMC content expressed as fraction of
the total plaque area. Because no difference was found
in total plaque area this indicates a reduction in the
fibrous cap thickness as is also shown in Figure 1A
and B. Interestingly, there was also a marked reduc-
tion in fibrous cap area when 40-week-old control
mice were compared with 20-week-old control mice
Table 2. Presence of MMP-2 and -9 antigens in the atherosclerotic
lesions of Cpn-infected and mock-infected mice of group A and B.
Staining is analysed by semi-quantitative measurements (0, 1 or 2)
and expressed as meanSD.
n MMP-9 MMP-2
Group A
Cpn 8 0.75 0.46  1.50 0.55 y
Control 8 0.25 0.46 0.83 0.41
Group B
Cpn 7 0.86 0.38 1.43 0.53 z
Control 7 0.57 0.53 1.00 0.00
 Statistical significant increase in MMP-9 (p5 0.05) in group A.
{ Statistical significant increase in MMP-2 (p5 0.05) in Group A.
{ Statistical significant increase in MMP-2 (p5 0.05) in Group B.
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as shown in Figure 1. This suggests that even under
normal conditions plaques become prone to rupture
as these mice become older which is in line with recent
observations of plaque rupture in atherosclerotic
mice.28 Our results demonstrate that Cpn accelerates
this process.
Thinning of the fibrous cap may results from acti-
vation of MMPs. The potential association of MMP
induced collagen degradation and fibrous cap thin-
ning has been affirmed by Shah et al. who demon-
strated that human monocyte-derived macrophages
in vitro induce collagen breakdown in fibrous caps of
human atherosclerotic plaques dissected from the
carotid artery and aorta.29 Using in situ zymography,
Galis et al. showed MMP activity in frozen sections of
atherosclerotic but not in non-atherosclerotic arterial
tissue.27 Therefore, the presence of MMP-2 and -9 in
the atherosclerotic lesions of LDLr/ApoEÿ/ÿ mice
was evaluated. A marked up-regulation of both
MMP's was observed both after two and six inocula-
tions with Cpn and this observation may provide an
explanation how Cpn reduces the fibrous cap.
A potential limitation of this study is that the pres-
ence of MMP-2 and -9 was performed by semi-quan-
titative analysis instead of quantitative analysis by
means of zymography and real time RT-PCR.
Although increase in MMP-2 and -9 immunoreactivity
was observed in plaques of Cpn-infected mice, no
double staining for MMPs and cell markers was per-
formed in this study to determine to which cells the
immunoreactivity was confined. However, zymogra-
phy, real time RT-PCR and certain cell marker stain-
ings are only possible on frozen tissue samples, which
were not available in the current study since all mice
were perfusion fixed with formaldehyde. Since the
present results provide, to our knowledge, new
insights concerning the role of Cpn in atherosclerosis,
we decided to publish the current MMP data.
A major characteristic of rupture prone, unstable
atherosclerotic plaques is the thinning of the fibrous
cap. Nonetheless, vulnerable plaques also show other
characteristics such as a reduced collagen content, an
increased lipid core content and an increased number
of T cells in the plaque.30 These characteristics were
not evaluated in the present study. Furthermore, when
Cpn reduces plaque stability an increased mortality
may be anticipated in infected mice. Survival studies
will be needed to prove this concept.
In conclusion our results suggest that Cpn infection
does not aggravate the atherosclerotic process with
the formation of larger lesions in LDLr/ApoEÿ/ÿ
mice but initiates a cascade of events, such as the
activation of MMPs, ultimately resulting in thinning
of the fibrous cap. To our knowledge this is the first
study to demonstrate an in vivo mechanism that may
explain the increased incidence of myocardial infarc-
tion among Cpn positive coronary heart disease apart
from the initially suggested aggravation of athero-
sclerotic plaque formation.
Acknowledgements
This study was supported by a grant from Pfizer BV, Capelle aan de
IJssel, The Netherlands. We thank GELM Grauls and SB Herngreen,
Department of Medical Microbiology, Maastricht University for
assistance of animal experiments and Cpn PCR analysis.
References
1 Gupta S, Leatham EW, Carrington D, Mendall MA,
Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies,
cardiovascular events, and azithromycin in male survivors of
myocardial infarction. Circulation 1997; 96: 404±407.
2 Wiesli P, Czerwenka W, Meniconi A et al. Roxithromycin
treatment prevents progression of peripheral arterial occlusive
disease in Chlamydia pneumoniae seropositive men: a rando-
mized, double-blind, placebo-controlled trial. Circulation 2002;
105: 2646±2652.
3 Heuschmann PU, Neureiter D, Gesslein M et al. Association
between infection with Helicobacter pylori and Chlamydia
pneumoniae and risk of ischemic stroke subtypes: results from a
population-based case-control study. Stroke 2001; 32: 2253±2258.
4 Saikku P, Leinonen M, Mattila K et al. Serological evidence of
an association of a novel Chlamydia, TWAR, with chronic cor-
onary heart disease and acute myocardial infarction. Lancet 1988;
2: 983±986.
5 Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME.
Chlamydia pneumoniae infection and mortality from ischaemic
heart disease: large prospective study. BMJ 2000; 321: 204±207.
6 Chandra HR, Choudhary N, O'Neill C, Boura J, Timmis GC,
O'Neill WW. Chlamydia pneumoniae exposure and inflammatory
markers in acute coronary syndrome (CIMACS). Am J Cardiol
2001; 88: 214±218.
7 Blessing E, Kuo CC, Lin TM et al. Foam cell formation inhibits
growth of Chlamydia pneumoniae but does not attenuate
Chlamydia pneumoniae-induced secretion of proinflammatory
cytokines. Circulation 2002; 105: 1976±1982.
8 Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D.
Chlamydia pneumoniae and chlamydial heat shock protein 60 sti-
mulate proliferation of human vascular smooth muscle cells via
toll-like receptor 4 and p44/p42 mitogen-activated protein
kinase activation. Circ Res 2001; 89: 244±250.
9 Vehmaan-Kreula P, Puolakkainen M, Sarvas M, Welgus HG,
Kovanen PT. Chlamydia pneumoniae proteins induce secretion of
the 92-kDa gelatinase by human monocyte-derived macro-
phages. Arterioscler Thromb Vasc Biol 2001; 21: E1±E8.
10 Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat
shock protein 60 localizes in human atheroma and regulates
macrophage tumor necrosis factor-alpha and matrix metallo-
proteinase expression. Circulation 1998; 98: 300±307.
11 Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT,
Kuo CC. Chlamydia pneumoniae infection accelerates the progres-
sion of atherosclerosis in apolipoprotein E-deficient mice. J Infect
Dis 1999; 180: 238±241.
12 Muhlestein JB, Anderson JL, Hammond EH et al. Infection
with Chlamydia pneumoniae accelerates the development of ather-
osclerosis and treatment with azithromycin prevents it in a
rabbit model. Circulation 1998; 97: 633±636.
94 R. Ezzahiri et al.
Eur J Vasc Endovasc Surg Vol 26, July 2003
13 Stary HC, Chandler AB, Dinsmore RE et al. A definition of
advanced types of atherosclerotic lesions and a histological
classification of atherosclerosis. A report from the Committee
on Vascular Lesions of the Council on Arteriosclerosis,
American Heart Association. Arterioscler Thromb Vasc Biol 1995;
15: 1512±1531.
14 Ezzahiri R, Nelissen-Vrancken H, Kurvers H et al. Chlamy-
dophila pneumoniae (Chlamydia pneumoniae) accelerates forma-
tion of complex atherosclerotic lesion in Apo E3-Leiden mice.
Cardiovasc Res 2002; 56: 269±276.
15 Bloemenkamp DG, Mali WP, Tanis BC et al. Chlamydia pneumo-
niae, Helicobacter pylori and cytomegalovirus infections and the
risk of peripheral arterial disease in young women. Atherosclerosis
2002; 163: 149±156.
16 Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumo-
niae and the risk of first ischemic stroke: The Northern
Manhattan Stroke Study. Stroke 2000; 31: 1521±1525.
17 Roblin PM, Dumornay W, Hammerschlag MR. Use of HEp-2
cells for improved isolation and passage of Chlamydia
pneumoniae. J Clin Microbiol 1992; 30: 1968±1971.
18 Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamy-
dia are dependent on serum cholesterol and specific to Chlamydia
pneumoniae. J Clin Invest 1999; 103: 747±753.
19 Lutgens E, Daemen M, Kockx M et al. Atherosclerosis in
APOE3-Leiden transgenic mice: from proliferative to atheroma-
tous stage. Circulation 1999; 99: 276±283.
20 Tong CY, Sillis M. Detection of Chlamydia pneumoniae and
Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993;
46: 313±317.
21 Aalto-Setala K, Laitinen K, Erkkila L et al. Chlamydia
pneumoniae does not increase atherosclerosis in the aortic root
of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol
2001; 21: 578±584.
22 Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H,
Hansson GK. Chlamydia pneumoniae infection does not induce
or modify atherosclerosis in mice. Circulation 2001; 103:
2834±2838.
23 Song YG, Kwon HM, Kim JM et al. Serologic and histopathologic
study of Chlamydia pneumoniae infection in atherosclerosis: a
possible pathogenetic mechanism of atherosclerosis induced by
Chlamydia pneumoniae. Yonsei Med J 2000; 41: 319±327.
24 Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of
systemic dissemination of Chlamydia pneumoniae via macro-
phages in the mouse. J Infect Dis 1998; 177: 1322±1325.
25 Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms lead-
ing to myocardial infarction: insights from studies of vascular
biology. Circulation 1994; 90: 2126±2146.
26 Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc
Biol 1997; 17: 1859±1867.
27 Galis Z, Sukhova G, Lark M, Libby P. Increased expression of
matrix metalloproteinases and matrix degrading activity in vul-
nerable regions of human atherosclerotic plaques. J Clin Invest
1994; 94: 2493±2503.
28 Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G,
Schwartz SM. Advanced atherosclerotic lesions in the innomi-
nate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc
Biol 2000; 20: 2587±2592.
29 Shah P, Falk E, Badimon J et al. Human monocyte-derived
macrophages induce collagen breakdown in fibrous caps of
atherosclerotic plaques. Potential role of matrix-degrading
metalloproteinases and implications for plaque rupture. Circula-
tion 1995; 92: 1565±1569.
30 Lutgens E, Gijbels M, Smook M et al. Transforming growth
factor-beta mediates balance between inflammation and fibrosis
during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22:
975±982.
Accepted 11 February 2003
Chlamydia pneumoniae Infection 95
Eur J Vasc Endovasc Surg Vol 26, July 2003
